Loading provider…
Loading provider…
Neurology Physician in Nashville, TN
NPI: 1356667745Primary Practice Location
VANDERBILT UNIVERSITY MEDICAL CENTER
2200 Childrens Way, Nashville, TN
Primary Employer
Vanderbilt Medical Group
vanderbilthealth.com
HQ Phone
Get MD Alexander's Phone Numberphone_androidMobile
Get MD Alexander's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
TN State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 55 | 86 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 53 | 68 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 32 | 32 |
| 4 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | 20 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 13 | 13 |
Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease.
Authors: Zhijian Chen, Yazmin Odia, Matthew Hall, Manmeet Ahluwalia, Rupesh Kotecha, Minesh Mehta
Publication Date: 2024-05
Authors: Michelle Leppert, Theresa Pacheco
Journal: Am J Dermatopathol
Lead Sponsor: NovoCure GmbH
Intervention / Treatment: DEVICE: NovoTTF-200M device, OTHER: Best Standard of Care
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: Genentech, Inc., National Cancer Institute (NCI), GlaxoSmithKline, Brain Science Foundation
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Vismodegib, DRUG: Capivasertib, DRUG: FAK Inhibitor GSK2256098
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Sunitinib Malate, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Osimertinib, PROCEDURE: Biospecimen Collection, DRUG: Dabrafenib, DRUG: Crizotinib, DRUG: Sapanisertib, DRUG: Taselisib, PROCEDURE: Computed Tomography, BIOLOGICAL: Trastuzumab, DRUG: Trametinib, PROCEDURE: Multigated Acquisition Scan, DRUG: Palbociclib, DRUG: Afatinib, DRUG: Ulixertinib, OTHER: Cytology Specimen Collection Procedure, DRUG: Dasatinib, DRUG: Vismodegib, DRUG: Afatinib Dimaleate, DRUG: Adavosertib, PROCEDURE: Biopsy Procedure, DRUG: Defactinib, PROCEDURE: Radionuclide Imaging, BIOLOGICAL: Trastuzumab Emtansine, DRUG: Copanlisib, PROCEDURE: Echocardiography Test, DRUG: PI3K-beta Inhibitor GSK2636771, DRUG: Larotrectinib, BIOLOGICAL: Relatlimab, DRUG: Copanlisib Hydrochloride, DRUG: Capivasertib, DRUG: Erdafitinib, DRUG: Larotrectinib Sulfate, DRUG: Binimetinib, BIOLOGICAL: Pertuzumab, DRUG: Ipatasertib, DRUG: Dabrafenib Mesylate, DRUG: Defactinib Hydrochloride, DRUG: Fexagratinib, PROCEDURE: Radiologic Examination